Analyst ratings can significantly affect a stock's performance in the short term as they reflect changes in expectations about the company's future performance. A downgrade from Overweight to Equal-Weight suggests that Barclays sees less upside potential in Immunogen, which could lead to a negative investor reaction and a potential decrease in the stock price.